AI Article Synopsis
- Rheumatoid arthritis (RA) is an autoimmune disease that leads to chronic inflammation of joints and tissues, and gut microbiota changes may play a key role in immune dysfunction associated with RA.
- Treatments for RA may influence gut microbiota diversity, suggesting that maintaining or modifying gut bacteria could be an important strategy for managing the disease.
- In a study, B. coagulans BACO-17 showed promise as a new treatment by reducing symptoms of RA and protecting joint tissues, indicating its potential for further research as a therapeutic option.
Article Abstract
Rheumatoid arthritis (RA) is an autoimmune disease that causes persistent inflammation involving the joints, cartilage, and synovium. In individuals with RA, alterations in the composition of intestinal bacteria suggest the vital role of gut microbiota in immune dysfunction. Multiple therapies commonly used to treat RA can also alter the diversity of gut microbiota, further suggesting the modulation of gut microbiota as a prevention or treatment for RA. Therefore, a better understanding of the changes in the gut microbiota that accompany RA should facilitate the development of novel therapeutic approaches. In this study, B. coagulans BACO-17 not only significantly reduced paw swelling, arthritis scores, and hind paw and forepaw thicknesses but also protected articular cartilage and the synovium against RA degeneration, with a corresponding downregulation of TNF-α expression. The inhibition or even reversing of RA progression highlights B. coagulans BACO-17 as a novel therapeutic for RA worth investigating.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.intimp.2024.112863 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!